Endocrine Disorders During Anti-Tumor Therapy with Checkpoint Inhibitors

Author:  Lozanov, Lachezar B. 1

1 Clinic of Internal Diseases, Department of Endocrinology, Acibadem City Clinic, UMHAT Tokuda Hospital, Sofia

Abstracts:

Immune checkpoint inhibitors (ICIs) are in creasingly the mainstay of treatment for multiple malignancies and have become the therapeutic standard for a number of malignancies due to their efficacy based on antitumor immune response and subsequent impact on overall survival.

However, due to their association with au toimmunity, ICIs lead to various side effects that involve multiple organs, including the endocrine system. Hypothyroidism, hyperthyroidism, hy pophysitis, primary adrenal insufficiency, and au toimmune diabetes mellitus are the most frequent ly reported endocrinopathies. Early diagnosis and management of the endocrine side effects of this treatment can reduce morbidity and mortality in affected patients.

 

Download the full issue 2/2024

Endocrinologia bg-flag

Journal of the Bulgarian Society of Endocrinology

How to treat?